Back to Search Start Over

Brigatinib as a treatment of ALK-positive non-small cell lung cancer

Authors :
Alberto Revelant
Alessandra Bearz
Brigida Stanzione
Elisa De Carlo
Alessandro Del Conte
Source :
Expert Review of Precision Medicine and Drug Development. 6:299-305
Publication Year :
2021
Publisher :
Informa UK Limited, 2021.

Abstract

Anaplastic lymphoma kinase (ALK) gene rearrangements and resulting fusion proteins occur in 3%-7% of patients with non-small-cell lung cancer (NSCLC), conferring sensitivity to treatment with ALK T...

Subjects

Subjects :
Pharmacology
Brigatinib
business.industry
ALK-Positive
medicine.disease
Fusion protein
respiratory tract diseases
hemic and lymphatic diseases
Drug Discovery
Genetics
medicine
Cancer research
Molecular Medicine
Anaplastic lymphoma kinase
Non small cell
Target therapy
Lung cancer
business
Gene

Details

ISSN :
23808993
Volume :
6
Database :
OpenAIRE
Journal :
Expert Review of Precision Medicine and Drug Development
Accession number :
edsair.doi...........3ebe85e71ebf066413a169e62c06b396

Tools

Authors Abstract Subjects Details